Compare Unity Software Inc (U) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unity Software Inc vs Viatris Inc — how do they compare? Unity Software Inc trades at $46.65 (market cap $20.20B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Unity Software Inc and Viatris Inc are close in size by market cap, and Viatris Inc pays a 2.75% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Unity Software Inc for 50 Days and Viatris Inc for 57 Days on average.
| U | VTRS | |
|---|---|---|
Market Cap | $20.20B | $20.03B |
Volume | 15,432,191 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $49.47 | $18.27 |
52-Week Low | $17.13 | $9.74 |
Typical Hold Time | 50 Days | 57 Days |
Enterprise Value | $20.08B | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unity Software (U) trades at $46.77, up 2.93% with strong bullish momentum. The stock shows improving fundamentals with revenue stabilizing around $1.8B and narrowing losses, though still unprofitable. Technical indicators signal bullish sentiment with the current price near resistance at $47. Recent news highlights Meta VR partnership driving positive sentiment, while analyst consensus remains strongly bullish with 82.76% buy ratings.
Unity presents a growth opportunity with strategic partnerships and improving financial trends, but faces significant execution risks. The company's high valuation multiples and persistent losses require careful monitoring of profitability progress. Near-term catalysts include VR market expansion and advertising platform growth, though competitive pressures and macroeconomic uncertainty remain key concerns.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
